Literature DB >> 21388346

Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?

Niki Katsiki1, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis.   

Abstract

Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk. Furthermore, certain drugs (e.g. lipid and blood pressure lowering) that decrease)cardiovascular risk and improve/preserve renal function were shown to influence serum uric acid (SUA) levels and/or NAFLD. A link between hyperuricaemia and NAFLD has also been suggested. This review considers the associations between hyperuricaemia, NAFLD and vascular risk. We also discuss the effects of different drug treatments on SUA and NAFLD. As NAFLD is a very common condition, future work in this field is needed with regard to a more practical definitive diagnosis, evidence- based treatments and a better understanding of the possible links between NAFLD, elevated SUA levels, cardiovascular disease and chronic kidney disease. Whether treating hyperuricaemia and NAFLD will translate into a reduced risk of vascular events requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21388346     DOI: 10.2174/157016111797484152

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  14 in total

1.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Michael S Kostapano; Niki Katsiki; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Oman Med J       Date:  2012-03

Review 2.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.

Authors:  Konstantinos Kargiotis; Vasilios G Athyros; Olga Giouleme; Niki Katsiki; Evangelia Katsiki; Panagiotis Anagnostis; Chrysoula Boutari; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 4.  Dapagliflozin in patients with type 2 diabetes mellitus.

Authors:  Theodosios D Filippatos; Evangelos N Liberopoulos; Moses S Elisaf
Journal:  Ther Adv Endocrinol Metab       Date:  2015-02       Impact factor: 3.565

Review 5.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Licia Polimeni; Maria Del Ben; Francesco Baratta; Ludovica Perri; Fabiana Albanese; Daniele Pastori; Francesco Violi; Francesco Angelico
Journal:  World J Hepatol       Date:  2015-06-08

6.  Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9.

Authors:  Brian J DeBosch; Oliver Kluth; Hideji Fujiwara; Annette Schürmann; Kelle Moley
Journal:  Nat Commun       Date:  2014-08-07       Impact factor: 14.919

7.  Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus.

Authors:  N Papanas; M Demetriou; N Katsiki; K Papatheodorou; D Papazoglou; T Gioka; S Kotsiou; E Maltezos; D P Mikhailidis
Journal:  Exp Diabetes Res       Date:  2011-09-15

8.  IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.

Authors:  Vasilios G Athyros; Apostolos I Hatzitolios; Asterios Karagiannis; Christos Savopoulos; Niki Katsiki; Konstantinos Tziomalos; Aikaterini Papagianni; Anna Kakafika; Thomas D Gossios; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

9.  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

Authors:  Vassilios G Athyros; Olga Giouleme; Emmanouel S Ganotakis; Moses Elisaf; Konstantinos Tziomalos; Themistoklis Vassiliadis; Evangelos N Liberopoulos; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

10.  Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study.

Authors:  Vasilios G Athyros; Niki Katsiki; Konstantinos Tziomalos; Thomas D Gossios; Eleni Theocharidou; Eygenia Gkaliagkousi; Panagiotis Anagnostis; Efstathios D Pagourelias; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2013-05-28       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.